Dan L Duncan Comprehensive Cancer Center

Recent papers from Dan L Duncan Comprehensive Cancer Center

1. A viral replication level-dependent continuum of transcriptional and microRNA reprogramming in HIV-1-infected microglia links productive infection to neurocognitive-associated gene networksmBio · 2026
2. Transcriptional and DNA Methylation Changes in the Hippocampus and Prefrontal Cortex after Fractionated Cranial Radiation in Mice2026
3. Concurrent TP53 and ARID1A Mutations Are Associated with Adverse Survival Outcomes and Distinct Molecular Signatures in Pancreatic Ductal AdenocarcinomaCancers · 2026
4. Individualized AI-driven Neuromodulation Selectively Enhances and Reorganizes Human Tongue Sensorimotor Networks.2026
5. Hemolysis During Ex Vivo Lung Perfusion Is Associated with Endothelial Injury, Cytokine Release, and Primary Graft DysfunctionBioengineering · 2026
6. Germline structural variation involving gynecologic and breast cancers reveals polygenic signatures of tumor mutational loadGenome biology · 2026
7. Ten Years of Incidental, Secondary, and Actionable FindingsNew England Journal of Medicine · 2023
8. Macrophages in spatial context: cellular niches in lung diseaseFrontiers in Immunology · 2026
9. Supporting implementation of the national standards for cancer survivorship care: development of the cancer survivorship maturity model (CSMM)Journal of Cancer Survivorship · 2026
10. Leukemia-associated myeloid cells support distinct T-ALL subtypes via unique signals converging on metabolic alterationsBlood · 2026
11. Molecular stratification of SPOP-mutant prostate cancer demonstrates Wnt signaling and replication stress signatures in diverse patient populationsCell Reports · 2026
12. CAMKV kinase drives neuroblastoma growth and acts as a novel therapeutic targetThe Journal of Experimental Medicine · 2026
13. Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage EvaluationClinical Pharmacokinetics · 2026
14. Evaluating and validating immune effector dysfunction as a biomarker in bladder cancer.Journal of Clinical Oncology · 2026
15. Phase II open-label trial of neoadjuvant immunotherapy in combination with CAPOX for resectable non-metastatic proficient mismatch repair (pMMR) colon cancer: NICER study.Journal of Clinical Oncology · 2026
16. Utilization of risk-reducing interventions among breast cancer patients with pathogenic germline variants across safety-net and academic hospitals.Journal of Clinical Oncology · 2026
17. A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab (P).Journal of Clinical Oncology · 2026
18. MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy (PBC) in patients (pts) with locally advanced/metastatic urothelial cancer (la/mUC; Alliance A032001).Journal of Clinical Oncology · 2026
19. Impact of COVID-19 mRNA vaccines on survival outcomes in patients with solid tumors receiving immunotherapy: A large-scale retrospective study.Journal of Clinical Oncology · 2026
20. STRATOS-P clinical model for prognosis and selection of patients with metastatic hormone sensitive prostate cancer (mHSPC) for intermittent therapy.Journal of Clinical Oncology · 2026